1[1]Martin D, Abeloff James O, Armitage, et al. Clinical Oncology[ M ].Hracout Publishers Limited,2000.1047-1057.
2[2]Larrea L, dela Rubia, Jimenez C, et al. Cardiac tamponade and cardiogenic shock as a manifestation of all-trans retinoic acid syndrome: an association not previously reported [ J ]. Haematology, 1997,82 (4): 463-464.
3[3]Rammeloo LA, Postma A, Sobotka-plojhar MA, et al. Low-dose daunorubicin in induction treatment of childhood acute lymphoblastic leukemia: no long-time cardiac damage in a randomized study of the Dutch childhood leukemia study group [J]. Med Pediatr Oncol, 2000,35 ( 1 ):3-9.
4[4]Zalewska-Szewczyk B, Lipiec J, Bodalski S.Late cardiotoxicity of anthracyclines in children with acute leukemia[J]. Klin Pediatr, 1999,211(4) :356-359.
5[5]Riley LC, Hamn IM, Wheatrey K, et al. Treatment-related deaths during induction and first remission of acute myeloid leukemia in children treated on tenth medical research council acute myeloid leukemia trial (MRC AML 10) the MCR childhood leukemia working party[J].Br J Haematol, 1999,106(2) :436-444.
6[6]Lenk MK, Zeybek C, Okutan V, et al. Detection of early anthracycline induced cardiotoxicity in ch: ldhood cancer with dobutamine stress echocardiography[J] .Turk J Pediatr, 1998,40(3) :373-383.
7[7]Becher H, Tiemanni K, Kuntz S, et al. Recent advances in real-time myocardial peffusion imaging. The Sixth European Symposum on Ultrasound contrast Imaging[ M ]. Retterdam: The Netherlande, Abstract4,2001.25-26.
8[8]Nakamae H, Tsumura K, Hino M, et al . QT dispersion as a predictor of acute heart failure after high-dose cyclophosphamide[J]. Lancet, 2000,355(9206) :805-806.
9[9]Lipshultz SE, Rifai N, Sallan SE, et al. Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury[J]. Circulation, 1997,96(8) :2641-648.
10[10]Woodlock TJ, Lifton R, Disalle M. Coincident acute myelogenous Leukemia and ischemic heart disease: Use of the cardioprotectant dexrazoxane during induction chemotherapy[J]. Am J Hematol, 1998,59(3) :246-248.
同被引文献6
1Yeh ET, Tong AT, Lenihan DJ, et al. Cardiovascular complications of cancer therapy;Diagnosis, pathogenesis, and management[J]. Circulation, 2004, 109(25) : 3122-3133.
2Borensen K, Levitt G, Bull C. et al. Anthracycline dose in childhood acute lymphoblsstic leukemia:issues of early survival versus late cardiotoxicity[J]. J Clin Oncol, 1997,15 (1) : 61-68.
3潘宏铭,耿宝琴．肿瘤化疗的毒副作用[M]．上海：上海科技出版社．2001：46-52．
4Hale JP, Lewis IJ. Anthracyclines: Cardiotoxicity and its prevention[J]. Arch Dis Child, 1994, 71 (5) :459-462.
5Tassan-mangina S, Brasselet C, Nazeyrollas P, et al. Value of palsed Doppler tissue imaging for early detection myocardial dysfunction with anthracyclines[J]. Arch Mal Coeur Vaiss, 2002, 95(4):263-268.
6Kapusta L, Thijssen JM, Groot-loonen J, et al. Tissue Doppler imaging in detection of myocardia dysfunction in survivors of childhood cancer treatment with anthracyclines[J]. Ultrasound Med Biol, 2000, 26(7) : 1099-1108.
